Comparison	Therapies	Study	[n] intervention	[n] control	Duration	Treatment naive pat.
meglitinide vs. placebo	repaglinide vs. placebo: monotherapy	Chaung 1999	1.5 mg per day = 36; 6mg per day = 34	22	24 weeks	Mixture (no details)
		Goldberg 1998	67	33	18 weeks	All Treated
		Jovanovic 2000	3 mg per day = 140; 12mg per day = 146	75	24 weeks	Mixture (23% treatment Naive in placebo group; 27‐28% treatment naive in treatment groups)
		Moses 2001	270	138	16 weeks	All Treatment Naive
		van Gaal 2001	13	13	10 weeks	All Treatment Naive
	repaglinide vs. placebo: combination therapy with metformin	Moses 1999	29	27	16‐20 weeks	All Treated
	nateglinide vs. placebo: monotherapy	Bengel 2004	33	14	16 weeks	Mixture (no details)
		Hanefeld 2000	90 mg per day = 51; 180 mg per day = 58; 360 mg per day =63; 540 mg per day = 57	60	12 weeks	All Treatment Naive
		Horton 2000	179	172	24 weeks	Mixture (no details)
		Saloranta 2002	90 mg per day =166; 180 mg per day = 175; 360 mg per day = 171	163	24 weeks	All Treatment Naive
	nateglinide vs. placebo: combination therapy with metformin	Horton 2000	172	176	24 weeks	Mixture (no details)
		Marre 2002	180 mg per day = 155; 360 mg per day = 160	152	24 weeks	All Treated
repaglinide vs. nateglinide	Monotherapy	Rosenstock 2004	76 (repaglinide)	74 (nateglinide)	16 weeks	Mixture (no details)
	combination therapy with metformin	Raskin 2003	96 (repaglinide)	96 (nateglinide)	16 weeks	All Treated
meglitinides vs. metformin	repaglinide vs. metfomin: monotherapy	Derosa 2003	56	56	60 weeks	All Treatment Naive
		Moses 1999	29	27	16‐20 weeks	All Treated
	repaglinide vs. metfomin: combination therapy with insulin	Furlong 2002	39	41	13 weeks	All Treated
	nateglinide vs. metformin: monotherapy	Horton 2000	179	176	24 weeks	Mixture (no details)